Potomac Capital Management Inc. purchased a new position in Evolus, Inc. (NASDAQ:EOLS – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 141,172 shares of the company’s stock, valued at approximately $939,000. Potomac Capital Management Inc. owned approximately 0.22% of Evolus as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also modified their holdings of the business. Fox Run Management L.L.C. grew its holdings in shares of Evolus by 20.1% during the fourth quarter. Fox Run Management L.L.C. now owns 32,664 shares of the company’s stock worth $217,000 after buying an additional 5,459 shares in the last quarter. State of Wyoming purchased a new stake in shares of Evolus during the fourth quarter worth $63,000. Larson Financial Group LLC grew its holdings in shares of Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares in the last quarter. Pinnacle Associates Ltd. grew its holdings in shares of Evolus by 15.9% during the fourth quarter. Pinnacle Associates Ltd. now owns 782,365 shares of the company’s stock worth $5,203,000 after buying an additional 107,490 shares in the last quarter. Finally, Versor Investments LP purchased a new stake in shares of Evolus during the fourth quarter worth $178,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.
Evolus Trading Up 0.3%
Shares of EOLS stock opened at $6.70 on Wednesday. The company’s 50-day moving average price is $5.56 and its 200-day moving average price is $5.56. The stock has a market cap of $441.26 million, a price-to-earnings ratio of -10.00 and a beta of 1.34. Evolus, Inc. has a twelve month low of $3.86 and a twelve month high of $10.62.
Analyst Upgrades and Downgrades
EOLS has been the subject of a number of research reports. BTIG Research reaffirmed a “buy” rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th. Weiss Ratings lowered shares of Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Finally, Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.
Insider Activity
In other news, insider Rui Avelar sold 29,996 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $146,680.44. Following the transaction, the insider owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. The trade was a 6.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Moatazedi sold 116,720 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total transaction of $570,760.80. Following the transaction, the insider directly owned 618,369 shares in the company, valued at approximately $3,023,824.41. The trade was a 15.88% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 163,504 shares of company stock worth $797,184. Corporate insiders own 5.00% of the company’s stock.
Evolus Profile
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Read More
- Five stocks we like better than Evolus
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS – Free Report).
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
